Cempra’s Phase 3 Hit Its Primary Endpoints, But Not Without Caveats
Research - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
PremiumSearch Results for cempra
Cempra’s SOLITAIRE-IV Results are Just Months Away
Research - Cempra (CEMP) announced on Tuesday that enrollment in the phase III SOLITAIRE-IV trial is complete, and the company expects data from the study in the … Continue Reading
Read nowCempra Continues to Derisk Lead Asset, Solithromycin
Research - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading
PremiumCempra’s Phase 3 Trial Enrolled Faster than Expected
Insights - Cempra, Inc. (CEMP) enrolled patients in SOLITAIRE-Oral, a phase 3 trial of lead antibiotic solithromycin, slightly faster than expected, announcing completion on Thursday that puts a … Continue Reading
Read now
Cempra: Safety Results Solidifying Market Position
Insights - It looks like a risk associated with some approved antibiotics may not be a concern for Cempra’s (CEMP) own late-stage candidate, solithromycin. Cempra announced on … Continue Reading
Read now
Cempra Pipeline Update Holds Few Surprises
Insights - On Monday after the close, Cempra (CEMP) updated investors on its pipeline progress. We saw no major surprises and consider the update net-neutral, if not –positive. Read … Continue Reading
Read now
February Webinar: Your Questions, Answered
Research - A recording of last night’s webinar is ready and available for on-demand viewing. This month focused almost exclusively on your requested topics/companies. Timestamps: 2:00 Macro … Continue Reading
Premium